| 1 | 1 | | 86R13084 JG-F |
|---|
| 2 | 2 | | By: Hall S.B. No. 2350 |
|---|
| 3 | 3 | | |
|---|
| 4 | 4 | | |
|---|
| 5 | 5 | | A BILL TO BE ENTITLED |
|---|
| 6 | 6 | | AN ACT |
|---|
| 7 | 7 | | relating to the prohibited administration of certain vaccinations. |
|---|
| 8 | 8 | | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|---|
| 9 | 9 | | SECTION 1. Subchapter A, Chapter 161, Health and Safety |
|---|
| 10 | 10 | | Code, is amended by adding Section 161.0045 to read as follows: |
|---|
| 11 | 11 | | Sec. 161.0045. ADMINISTRATION OF CERTAIN VACCINES |
|---|
| 12 | 12 | | PROHIBITED. A health care provider may administer a vaccine only |
|---|
| 13 | 13 | | if: |
|---|
| 14 | 14 | | (1) the study relied on by the United States Food and |
|---|
| 15 | 15 | | Drug Administration for approval of the vaccine evaluated the |
|---|
| 16 | 16 | | safety of the vaccine against a control group that received: |
|---|
| 17 | 17 | | (A) a placebo; or |
|---|
| 18 | 18 | | (B) another vaccine or other substance approved |
|---|
| 19 | 19 | | by the United States Food and Drug Administration based on a study |
|---|
| 20 | 20 | | that evaluated the safety of that vaccine or substance against a |
|---|
| 21 | 21 | | control group that received a placebo for that study; |
|---|
| 22 | 22 | | (2) the study relied on by the United States Food and |
|---|
| 23 | 23 | | Drug Administration for approval of the vaccine evaluated the |
|---|
| 24 | 24 | | safety of the vaccine for a sufficient time to identify potential |
|---|
| 25 | 25 | | autoimmune, neurological, or chronic health conditions that may |
|---|
| 26 | 26 | | arise on or after the first anniversary of the date the vaccine is |
|---|
| 27 | 27 | | administered; |
|---|
| 28 | 28 | | (3) the vaccine has been evaluated for the vaccine's |
|---|
| 29 | 29 | | potential to: |
|---|
| 30 | 30 | | (A) cause cancer; |
|---|
| 31 | 31 | | (B) mutate genes; |
|---|
| 32 | 32 | | (C) affect fertility or cause infertility; and |
|---|
| 33 | 33 | | (D) cause autism spectrum disorder; |
|---|
| 34 | 34 | | (4) the department has posted on the department's |
|---|
| 35 | 35 | | Internet website a disclosure of any known injuries or diseases |
|---|
| 36 | 36 | | caused by the vaccine and the rate at which the injuries or diseases |
|---|
| 37 | 37 | | have occurred; and |
|---|
| 38 | 38 | | (5) the chemical, pharmacological, therapeutic, and |
|---|
| 39 | 39 | | adverse effects of the vaccine and the rate of injury of the vaccine |
|---|
| 40 | 40 | | when administered with other vaccines have been studied and |
|---|
| 41 | 41 | | verified. |
|---|
| 42 | 42 | | SECTION 2. This Act takes effect September 1, 2019. |
|---|